Top Stock Reports for GE Aerospace, Shell & McKesson
View original at finance.yahoo.comTop Stock Reports for GE Aerospace, Shell & McKesson Tuesday, March 17, 2026 The Zacks Research Daily presents the best research output of our analyst team…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Elite Pharmaceuticals remains sensitive to generic pricing pressure, DEA quota and API supply constraints, and customer concentration
60% confidenceElite Pharmaceuticals' generic lisdexamfetamine franchise is driving strong volume growth and establishing the product as a key revenue engine
60% confidenceMcKesson is delivering record revenues and expanding margins, supported by growth in specialty pharmaceuticals, oncology services, RxTS, and GLP-1 distribution
60% confidenceForeign exchange headwinds might be worrying for GE Aerospace
60% confidenceMcKesson's RxTS provides recurring, high-margin revenue streams
60% confidenceGE Aerospace has been witnessing strength in its businesses, driven by robust demand for commercial engines, propulsion and additive technologies
60% confidenceGeospace's Intelligent Industrial is developing subscription-based security products, such as the Heartbeat Detector, that add predictable revenue
60% confidenceMcKesson faces risks from revenue concentration with large customers, regulatory headwinds such as IRA and DSCSA, and execution challenges from the Medical-Surgical separation and ongoing M&A integration
60% confidenceRising U.S. & international defense budgets, geopolitical tensions, positive airline & airframer dynamics and robust demand for commercial air travel augur well for GE Aerospace
60% confidenceShell's net debt increased, while Chemicals and Renewables continue to weigh on returns amid weak margins
60% confidenceGeospace Technologies' liquidity has declined as working capital builds for contracts and receivable concentration adds risk
60% confidenceGeospace Technologies' $90 million PRM contract provides revenue visibility, and Pioneer land nodes expand GEOS' role in seismic exploration
60% confidenceFor Shell, strengths are offset by cyclical and segment-specific risks, justifying a neutral stance
60% confidenceMcKesson's acquisitions of PRISM and Core Ventures enhance its oncology footprint
60% confidenceShell's strengths are offset by cyclical and segment-specific risks, justifying a neutral stance
60% confidenceRising U.S. & international defense budgets, geopolitical tensions, positive airline & airframer dynamics and robust demand for commercial air travel augur well for GE Aerospace
60% confidenceShell demonstrated resilient cash generation in 2025, delivering robust operating and free cash flows, supporting shareholder returns
60% confidenceGeospace's near-term results reflect cyclical energy demand and margin pressure from low rental utilization
60% confidenceShell's LNG franchise remains a long-term strength, with solid sales growth and clear demand visibility
60% confidenceGeospace Technologies' near-term results reflect cyclical energy demand and margin pressure from low rental utilization
60% confidenceGeospace Technologies offers exposure to long-cycle infrastructure and energy markets across Smart Water, Intelligent Industrial and Energy Solutions
60% confidenceElite Pharmaceuticals' expansion into opioid analgesics diversifies the opportunity set
60% confidenceGE Aerospace has been witnessing strength in its businesses, driven by robust demand for commercial engines, propulsion and additive technologies
60% confidenceMcKesson is delivering record revenues and expanding margins, supported by growth in specialty pharmaceuticals, oncology services, RxTS, and GLP-1 distribution
60% confidenceGeospace Technologies offers exposure to long-cycle infrastructure and energy markets across Smart Water, Intelligent Industrial and Energy Solutions
60% confidenceGeospace Technologies' Smart Water benefits from demand for water infrastructure modernization and Hydroconn adoption, while the Aquana platform supports a shift to recurring revenue
60% confidenceElite Pharmaceuticals remains sensitive to generic pricing pressure, DEA quota and API supply constraints, and customer concentration
60% confidenceGeospace's liquidity has declined as working capital builds for contracts and receivable concentration adds risk
60% confidenceGE Aerospace expects organic revenues to grow in the low-double-digit range from the year-ago level for 2026
60% confidenceShell's LNG franchise remains a long-term strength, with solid sales growth and clear demand visibility
60% confidence